ENLIVEN THERAPEUTICS, INC. Payments to Acquire Marketable Securities
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Payments to Acquire Marketable Securities of $626.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $560.16M, a 133.22% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $65.84M, a 11.16% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $75.52M, a 35.18% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $71.86M, a 26.92% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2025 was $446.79M, a 27.39% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2024 was $350.74M, a 30.74% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2023 was $268.26M.
- ENLIVEN THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $560.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $626.00M 10-Q · filed 2026-08-05 | $701.52M derived: sum of 3 quarters · filed 2026-08-05 | $773.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $65.84M 10-Q · filed 2026-05-07 | $141.36M derived: sum of 2 quarters · filed 2026-05-07 | $213.22M derived: sum of 3 quarters · filed 2026-05-07 | $453.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $75.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $147.38M derived: sum of 2 quarters · filed 2026-03-03 | $387.57M derived: sum of 3 quarters · filed 2026-08-05 | $446.79M 10-K · filed 2026-03-03 |
| 2025-09-30 | $71.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $312.05M derived: sum of 2 quarters · filed 2026-08-05 | $371.27M 10-Q · filed 2025-11-12 | $487.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $240.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $299.41M 10-Q · filed 2026-08-05 | $415.93M derived: sum of 3 quarters · filed 2026-08-05 | $472.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $59.23M 10-Q · filed 2026-05-07 | $175.74M derived: sum of 2 quarters · filed 2026-05-07 | $232.36M derived: sum of 3 quarters · filed 2026-05-07 | $353.19M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $116.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $173.13M derived: sum of 2 quarters · filed 2026-03-03 | $293.96M derived: sum of 3 quarters · filed 2026-03-03 | $350.74M 10-K · filed 2026-03-03 |
| 2024-09-30 | $56.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $177.45M derived: sum of 2 quarters · filed 2025-11-12 | $234.22M 10-Q · filed 2025-11-12 | $275.52M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $120.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $177.61M 10-Q · filed 2025-08-13 | $218.91M derived: sum of 3 quarters · filed 2025-08-13 | $294.44M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $56.78M 10-Q · filed 2025-05-14 | $98.08M derived: sum of 2 quarters · filed 2025-05-14 | $173.61M derived: sum of 3 quarters · filed 2025-05-14 | $325.04M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $41.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $116.83M derived: sum of 2 quarters · filed 2025-03-13 | $268.26M derived: sum of 3 quarters · filed 2025-03-13 | $268.26M 10-K · filed 2025-03-13 |
| 2023-09-30 | $75.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $226.96M derived: sum of 2 quarters · filed 2024-11-13 | $226.96M 10-Q · filed 2024-11-13 | $226.96M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $151.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $151.43M 10-Q · filed 2024-08-13 | $151.43M derived: sum of 3 quarters · filed 2024-08-13 | $151.43M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | $0.00 derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |